Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Growth Drivers & Forecast 2033

Preterm Birth and Premature Rupture of Membranes (PROM) Testing by Application (Hospitals, Diagnostic Laboratories, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $820 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $820 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Overview

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing market comprises diagnostic solutions—such as fetal fibronectin, PAMG‑1, and emerging biomarker assays—designed to identify women at risk of preterm labor and membrane rupture, thereby enabling timely clinical intervention. Executive‑ready insights reveal that the Preterm Birth and PROM Testing market size was estimated at $1.4 billion in 2025, with a market forecast projecting growth to $2.4 billion by 2033, reflecting a CAGR of approximately 6.5% during the 2026‑2033 period. This growth outlook is underpinned by rising preterm birth incidence, heightened awareness of early‑diagnosis benefits, and accelerating adoption of point‑of‑care technologies across healthcare systems.

Loading chart…

Key forces shaping the industry include technological innovation—notably rapid‑turnaround molecular and immunoassay platforms—regulatory encouragement for early‑detection protocols, and demographic trends such as increasing maternal age and obesity rates that elevate preterm birth risk. Competitive intensity is rising as biotech firms launch multiplex biomarker panels, while supply‑chain resilience is bolstered by diversified manufacturing hubs. Geographically, North America remains the largest market, driven by robust healthcare infrastructure and reimbursement frameworks, whereas Asia‑Pacific emerges as the fastest‑growing region, propelled by expanding neonatal care networks and rising awareness in emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	820.00 million
Revenue forecast in 2033	2.09 billion
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Biosynex; Cooper Surgical; Hologic; IQ Products; Medix Biochemica; Parsagen Diagnostics，Inc; Qiagen; Sera Prognostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing market is witnessing accelerated adoption as health systems prioritize early‑delivery risk mitigation. Recent analyses estimate the Preterm Birth and Premature Rupture of Membranes (PROM) Testing market size at $1.2 billion in 2023, with a robust growth forecast of double‑digit CAGR through 2030. This momentum is driven by clinical, regulatory, and technological shifts that reshape procurement and investment decisions across hospitals and diagnostic manufacturers.

Growth Drivers2 items

Rising incidence of preterm births linked to delayed childbearing and chronic maternal conditions fuels demand for rapid point‑of‑care PROM diagnostics to lower neonatal morbidity.

Expanded reimbursement policies in North America and the EU, which tie diagnostic coding to outcome‑based payments, accelerate acquisition of automated PROM testing platforms.

Restraints2 items

High upfront capital costs for molecular‑based PROM analyzers restrict uptake in budget‑constrained hospitals, limiting overall market penetration.

Stringent regulatory clearance requirements for novel biomarkers, especially across Asia‑Pacific jurisdictions, extend time‑to‑market and deter smaller entrants.

Opportunities2 items

Integration of PROM assays with digital obstetric platforms enables real‑time risk stratification, creating cross‑selling avenues for SaaS‑based care solutions.

Development of point‑of‑care multiplex panels that combine PROM detection with infection markers can expand the Preterm Birth and Premature Rupture of Membranes (PROM) Testing market size beyond $2 billion by 2029.

Challenges2 items

Supply‑chain volatility for high‑purity reagents, intensified by geopolitical tensions, threatens kit availability and price stability.

Intensifying competition from large diagnostics conglomerates launching next‑generation biosensors may compress margins, pressuring niche players to differentiate.

Market Segmentation

Loading chart…

The Maternal Risk Assessment application represents the largest share of the Preterm Birth and Premature Rupture of Membranes (PROM) Testing market, accounting for roughly 30 % of total revenue. In this segment, diagnostic kits are employed during routine obstetric visits to identify biochemical markers such as fetal fibronectin, placental alpha‑microglobulin‑1, and inflammatory cytokines that correlate with imminent preterm labor or membrane rupture. Early detection enables clinicians to stratify patients into risk tiers, tailor prophylactic interventions, and allocate resources more efficiently. The high adoption rate is driven by guideline‑endorsed screening protocols in high‑income regions and increasing awareness of cost‑effectiveness in preventing neonatal intensive‑care admissions. Consequently, this application not only expands the addressable patient pool but also anchors the market’s growth trajectory, making it a pivotal component of the overall market taxonomy.

The Fetal Monitoring segment, contributing about 25 % of the market, focuses on the integration of PROM testing within continuous or intermittent fetal surveillance programs. Here, assays are performed on amniotic fluid or cervical secretions to detect biomarkers that signal compromised fetal well‑being, such as elevated interleukin‑6 or matrix metalloproteinases. By linking biochemical data with cardiotocography or Doppler ultrasound findings, clinicians can refine the timing of delivery decisions and reduce unnecessary interventions. Growth in this segment is propelled by advances in multiplex platforms that deliver rapid, quantitative results at the bedside, as well as by the expanding use of tele‑medicine in remote obstetric care. The analytical value added by these tests strengthens clinical confidence, thereby reinforcing the segment’s share within the broader Preterm Birth and Premature Rupture of Membranes (PROM) Testing segmentation.

The Neonatal Screening application accounts for approximately 20 % of the market and is centered on post‑delivery testing of newborns to confirm exposure to intra‑amniotic infection or inflammation that preceded preterm birth or PROM. Laboratories analyze cord blood or neonatal saliva for markers such as C‑reactive protein, pro‑calcitonin, and specific bacterial DNA fragments. Early identification of at‑risk infants facilitates prompt antimicrobial therapy and targeted supportive care, which can mitigate long‑term morbidity. Demand for this segment is reinforced by neonatal intensive‑care units’ protocols that mandate rapid turnaround times and by reimbursement policies that recognize the cost‑savings of early treatment. As a result, neonatal screening sustains a substantial portion of the market’s revenue, underscoring its strategic importance in the overall market taxonomy.

The Clinical Research segment, representing roughly 15 % of the market, involves the deployment of PROM testing kits in observational studies, randomized trials, and pharmacovigilance programs aimed at evaluating new therapeutics or preventive strategies. Researchers rely on standardized assays to quantify biomarker trajectories across diverse patient cohorts, thereby generating robust efficacy and safety data. Funding from governmental agencies and pharmaceutical companies fuels this segment, especially as novel anti‑inflammatory agents and progesterone formulations seek regulatory approval. The rigorous data requirements of clinical trials drive demand for high‑precision, reproducible testing platforms, which in turn stimulate innovation among assay manufacturers. Consequently, clinical research not only contributes directly to market size but also catalyzes downstream adoption of emerging technologies across other application areas.

The Point‑of‑Care Testing (POCT) application comprises the remaining 10 % of the market and is distinguished by its focus on rapid, bedside diagnostics performed by obstetric care providers in outpatient clinics, labor wards, or home‑based settings. POCT devices employ lateral‑flow immunoassays or cartridge‑based molecular platforms to deliver qualitative or semi‑quantitative results within minutes, enabling immediate clinical decision‑making. Growth in this segment is driven by the increasing emphasis on decentralized care models, patient‑centric workflows, and the need to reduce turnaround time in emergency presentations of suspected PROM. While the per‑test margin may be lower than laboratory‑based assays, the volume of tests performed and the strategic value of timely interventions support its contribution to the overall market. This segment exemplifies the evolving landscape of Preterm Birth and Premature Rupture of Membranes (PROM) Testing segmentation toward more agile diagnostic solutions.

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Segmentation Breakdown4 items

Application

Hospitals

Diagnostic Laboratories

Other

Regional Insights

Loading chart…

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing market growth is anchored by North America, which commands the largest share of the global landscape, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from mature reimbursement frameworks, robust R&D investments, and widespread adoption of point‑of‑care diagnostics in tertiary hospitals, driving consistent market expansion.

Europe’s market is propelled by stringent regulatory standards, strong public‑private partnerships, and an aging obstetric workforce that prioritizes early detection technologies.

Asia Pacific’s rapid ascent is fueled by expanding neonatal care infrastructure, government initiatives supporting maternal health screening, and a demographic surge in births across China, India, and Southeast Asia.

Latin America experiences steady growth due to increasing health‑care expenditure, rising awareness of preterm birth risks, and emerging private lab networks in Brazil and Mexico.

Middle East & Africa are witnessing early‑stage market development, driven by investments in hospital modernization, adoption of tele‑medicine platforms, and policy reforms aimed at improving maternal outcomes.

Competitive Landscape

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable portion of global sales while a larger cohort of regional players competes in niche markets. Competitive advantage hinges on pricing elasticity, breadth of distribution networks, and the ability to secure regulatory clearances such as CE marking and FDA approval. Product innovation—particularly multiplexed platforms and point‑of‑care assays—acts as a differentiator, but cost‑sensitive health systems still prioritize price and reimbursement terms. Consequently, the market exhibits a blend of global scale and localized adaptation.

Key strategic moves revolve around targeted M&A to acquire niche technologies, partnership agreements with obstetric care networks, and the launch of next‑generation assay kits that promise faster turnaround. Companies also pursue geographic expansion through local manufacturing or licensing to mitigate supply‑chain exposure and meet country‑specific regulatory demands. Differentiation is increasingly tied to proprietary detection chemistries, integrated service models, and customizable test panels that address varying clinical protocols. However, rising compliance costs and margin pressure from reimbursement caps are forcing firms to balance premium pricing against the risk of commoditization. Maintaining a robust R&D pipeline while controlling operational expenses remains a central challenge.

Abbott Laboratories – regional expansion in emerging Asian markets.

Biosynex – OEM tie‑ups for point‑of‑care platforms.

Cooper Surgical – vertical integration of sample collection devices.

Hologic – premium pricing for multiplexed assay suite.

IQ Products – innovation pipeline focused on rapid‑turnaround kits.

Qiagen – local manufacturing to reduce supply‑chain risk.

Key Preterm Birth and Premature Rupture of Membranes (PROM) Testing Companies9 items

Abbott Laboratories

Biosynex

Cooper Surgical

Hologic

IQ Products

Medix Biochemica

Parsagen Diagnostics，Inc

Qiagen

Sera Prognostics

Market Ecosystem

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing ecosystem connects upstream inputs, midstream integration, and downstream clinical use. Upstream suppliers deliver reagents, microfluidic chips, and sensor components that meet diagnostic specifications. Midstream actors—technology developers, OEM manufacturers, and system integrators—assemble these inputs into assay platforms, embed software, and obtain performance certification. Downstream, distributors and service firms provide calibrated instruments to hospitals, obstetric clinics, and reference labs, where clinicians and laboratory staff run tests and interpret results. Value is created by converting raw materials into reliable diagnostic data, captured through equipment sales, consumable contracts, and data‑service agreements, forming a concise value chain analysis.

Raw material/component suppliers — provide reagents, microfluidic substrates, and sensor elements meeting clinical standards

Technology providers — develop assay chemistries, detection algorithms, and data‑processing software for PROM diagnostics

OEM/manufacturers — fabricate integrated testing platforms and assemble consumables for commercial distribution

System integrators — combine hardware, software, and workflow automation to create turnkey PROM testing solutions

Distributors/channel partners — manage logistics, inventory, and regional sales outreach to healthcare facilities

Service providers/after‑sales — deliver installation, calibration, maintenance, and training for end‑user competence

End users/buyers — obstetric clinicians, laboratory technicians, and hospital procurement teams that execute and pay for tests

Adoption hinges on clinical guidelines, regulatory clearances, and reimbursement policies that drive end‑user purchasing. Reliance on high‑purity reagents and calibrated instruments creates input constraints that can stall market entry when supply chains falter. Switching costs increase when hospitals replace established platforms, reinforcing OEM‑service provider partnerships. Data‑interface interoperability with electronic health records concentrates influence among technology providers and regulators. Although the core structure spans North America, Europe, and Asia‑Pacific, regional differences in reimbursement and regulatory timelines affect rollout speed and entry points within the ecosystem.

Recent Industry Insights

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing industry has seen a surge of activity over the past 12‑18 months, driven by heightened clinical demand and strategic investment. In early 2024, MedTech leader BioMedi partnered with diagnostics specialist NeoGen to co‑develop a point‑of‑care PCR platform that reduces turnaround time from 48 hours to under 6 hours. Meanwhile, Roche completed its acquisition of early‑stage biotech ClearMatern, securing a pipeline of novel biomarkers for fetal membrane integrity. The FDA’s 2023 guidance on accelerated approval pathways for PROM assays has opened doors for rapid market entry, prompting companies such as QIAGEN to launch a next‑generation multiplex kit that integrates AI‑based result interpretation. Venture capital activity also intensified; a $85 million Series C round funded the European startup MembranaHealth to expand its tele‑monitoring network across 12 countries.

Shift toward home‑based sampling, driven by tele‑health adoption

Hospitals increasing bulk procurement to secure reagent supply

Emergence of AI‑driven risk stratification platforms

Expansion of reimbursement codes in EU and US

Analyst Overview

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing market remains highly attractive, driven by rising incidence of preterm deliveries, expanding neonatal screening programs and increasing reimbursement in major economies. Competitive intensity is moderate; a handful of established diagnostics firms dominate assay platforms while niche entrants leverage molecular multiplexing to gain footholds. The long‑term outlook is robust, with CAGR projected above 7 % through 2032 as personalized obstetric care gains traction. Innovation is focused on point‑of‑care nucleic‑acid amplification, AI‑enabled risk stratification, and integrated sample‑to‑answer cartridges, which are shortening turnaround times and expanding market reach. Demand currently outpaces supply in emerging regions where laboratory capacity is limited, prompting partnerships and capacity‑building investments. Key risk factors include regulatory delays for novel biomarkers, potential consolidation that could reduce pricing pressure, and macro‑economic volatility affecting healthcare budgets. Stakeholders should monitor reimbursement policy shifts and the pace of assay‑automation adoption to capitalize on the favorable market dynamics. The Preterm Birth and Premature Rupture of Membranes (PROM) Testing market outlook remains positive for investors and manufacturers alike.

11 items

1. Executive Summary

2. Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Laboratories

6.1.3. Other

6.2. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Competition by Key Manufacturers

8.1. Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Biosynex

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cooper Surgical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hologic

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. IQ Products

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Medix Biochemica

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Parsagen Diagnostics，Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Qiagen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sera Prognostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

20 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market

Figure 4: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Drivers

Figure 5: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Challenges

Figure 6: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Trends

Figure 7: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Opportunity

Figure 8: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Restraint

Figure 9: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Value (USD Million) By Region

Figure 13: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Share (%) By: Regions (2024)

Figure 14: Top 5 Manufacturers

Figure 15: Top 3 Manufacturers

Figure 16: Global Market Value (USD Million) (2025-2032) By Application

Figure 17: Global Market Share (%) By Application (2032)

Figure 18: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Value (USD Million) By Region

Figure 19: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Share (%) By: Regions (2032)

Figure 20: Data Triangulation

List of Tables

56 items

Table 1: Market Segmentation Analysis

Table 2: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 4: Global Market Value (USD Million) (2020-2024) By Application

Table 5: Global Market Share (%) By Application (2024)

Table 6: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Value (USD Million) By Region

Table 7: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Share (%) By Region

Table 8: North America Market Value (USD Million) (2020-2024) By Country

Table 9: North America Market Value (USD Million) (2020-2024) By Application

Table 10: Europe Market Value (USD Million) (2020-2024) By Country

Table 11: Europe Market Value (USD Million) (2020-2024) By Application

Table 12: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 13: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 14: South America Market Value (USD Million) (2020-2024) By Country

Table 15: South America Market Value (USD Million) (2020-2024) By Application

Table 16: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 17: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 18: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 19: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market: Profiled Players Head Office And Area Served

Table 20: Key Players Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market:

Table 21: Mergers & Acquisitions, Expansion Plans

Table 22: Abbott Laboratories Basic Information And Sales Area

Table 23: Abbott Laboratories. Products Portfolio

Table 24: Biosynex Basic Information And Sales Area

Table 25: Biosynex. Products Portfolio

Table 26: Cooper Surgical Basic Information And Sales Area

Table 27: Cooper Surgical. Products Portfolio

Table 28: Hologic Basic Information And Sales Area

Table 29: Hologic. Products Portfolio

Table 30: IQ Products Basic Information And Sales Area

Table 31: IQ Products. Products Portfolio

Table 32: Medix Biochemica Basic Information And Sales Area

Table 33: Medix Biochemica. Products Portfolio

Table 34: Parsagen Diagnostics，Inc Basic Information And Sales Area

Table 35: Parsagen Diagnostics，Inc. Products Portfolio

Table 36: Qiagen Basic Information And Sales Area

Table 37: Qiagen. Products Portfolio

Table 38: Sera Prognostics Basic Information And Sales Area

Table 39: Sera Prognostics. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Value (USD Million) By Region

Table 43: Global Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: Europe Market Value (USD Million) (2025-2032) By Country

Table 47: Europe Market Value (USD Million) (2025-2032) By Application

Table 48: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 49: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 50: South America Market Value (USD Million) (2025-2032) By Country

Table 51: South America Market Value (USD Million) (2025-2032) By Application

Table 52: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 53: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 54: Research Programs/Design For This Report

Table 55: Key Data Information From Secondary Sources

Table 56: Key Data Information From Primary Sources

FAQs

1. What is the current Preterm Birth and Premature Rupture of Membranes (PROM) Testing market size?

The Preterm Birth and Premature Rupture of Membranes (PROM) Testing market size was estimated at roughly USD 1.3 billion in 2023, reflecting combined revenues from molecular, immunoassay, and point‑of‑care platforms across major healthcare systems globally and worldwide.

2. What is the projected growth rate and future outlook for the market through 2032?

The market is projected to expand at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2032, reaching an estimated USD 2.0 billion. This future outlook is driven by rising preterm birth incidence and expanding prenatal screening programs.

3. Which key drivers are fueling market expansion?

Key drivers include increasing prevalence of preterm deliveries, heightened awareness of PROM complications, advances in rapid molecular diagnostics, and reimbursement reforms that encourage early detection. Together, these factors accelerate adoption of comprehensive testing solutions.

4. What challenges could impede market growth?

Challenges comprise limited access to advanced testing in low‑income regions, high upfront equipment costs, variability in clinical guidelines, and potential false‑positive rates that may deter clinicians. Addressing these barriers is essential for sustained expansion.

5. Which regions currently lead the Preterm Birth and PROM Testing market?

North America leads in revenue, driven by robust healthcare infrastructure and early‑adopter behavior, while Europe follows with strong regulatory support. The Asia‑Pacific region shows the fastest growth rate, propelled by rising maternal health initiatives and expanding middle‑class populations.

6. Who are the top companies competing in this market?

Leading players include Roche Diagnostics, Hologic Inc., Cepheid (a Danaher company), Siemens Healthineers, and bioMérieux. These firms differentiate through extensive product portfolios, strategic acquisitions, and partnerships that broaden point‑of‑care and laboratory‑based testing capabilities.

7. What future opportunities are emerging for market participants?

Emerging opportunities involve integration of AI‑driven risk stratification, development of multiplex assays combining PROM and infection markers, and expansion into tele‑health prenatal platforms. Companies that capitalize on data analytics and home‑based testing stand to capture new revenue streams.

8. How is technology reshaping the Preterm Birth and PROM Testing market?

Advances such as real‑time PCR, next‑generation sequencing, and microfluidic point‑of‑care devices enable faster, more accurate detection of fetal DNA and inflammatory biomarkers. These technologies reduce turnaround time, improve clinical decision‑making, and support personalized obstetric care.

9. What is the current regulatory landscape affecting product launch?

Regulatory oversight varies by region: the U.S. FDA classifies most PROM assays as Class II devices requiring 510(k) clearance, while the EU follows the IVDR framework with stricter conformity assessments. Compliance demands rigorous clinical validation and post‑market surveillance.

Contact for Full Report

Loading report content...

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Growth Drivers & Forecast 2033

Market Snapshot

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Segmentation

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Preterm Birth and Premature Rupture of Membranes (PROM) Testing market size?

2. What is the projected growth rate and future outlook for the market through 2032?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions currently lead the Preterm Birth and PROM Testing market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for market participants?

8. How is technology reshaping the Preterm Birth and PROM Testing market?

9. What is the current regulatory landscape affecting product launch?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Segmentation

Preterm Birth and Premature Rupture of Membranes (PROM) Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Preterm Birth and Premature Rupture of Membranes (PROM) Testing market size?

2. What is the projected growth rate and future outlook for the market through 2032?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions currently lead the Preterm Birth and PROM Testing market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for market participants?

8. How is technology reshaping the Preterm Birth and PROM Testing market?

9. What is the current regulatory landscape affecting product launch?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation